ABSTRACT
The protective effects of the leaf powder of Picralima nitida in male rats were evaluated to establish its haematopoietic potential. To achieve this, albino rats (n = 30), weighing 120 - 160g were grouped into 5, labelled A to E. Groups C and D were intraperitoneally induced for anaemia with 0.1mg/kg body weight (b.wt) of phenyl hydrazine for 7 day. Groups A and B and C and D orally received 200 and 400 mg/kg b.wt of Picralima nitida leaf extract respectively for 14 days. Group E served as the control. Blood sample (5.0ml) was collected from each rat on days 8 and 15 and dispensed into ethylene diamine tetra acetic acid containers for haemogram using haematology auto analyser. The result showed that on day 8, Picralima nitida leaf extract produced a significant (P<0.05) increase in haemoglobin (Hb) and haematocrit (Hct) when compared with the control. On day 15, Picralima nitida leaf extract produced a significant (P<0.05) increase in the red blood cell (RBC), Hb and Hct when compared with the experimental control. The results indicate time-dependent haematopoiesis.
Subject(s)
Apocynaceae , Hematology , Male , Animals , Rats , Hematocrit , Acetic Acid , Plant Extracts/pharmacologyABSTRACT
Advances in single-cell technology and genetic mouse models have resulted in the identification of new types of hemopoietic stem cells (HSC), resulting in baffling observations, suggesting a reconsideration of the long-held notion that all hematopoietic cells in the adult are derived from HSCs. The existence of long-lived HSC-independent hematopoiesis has led to the conclusion that despite the single hierarchical differentiation route that generates functional blood types, other differentiation routes exist in-vivo. Heterogeneity in the HSC population and the evolving knowledge around HSC has translated to it's improved application as a therapeutic tool for various blood disorders. The reprogramming of non-hematopoietic somatic and mature blood cells to pluripotency with their subsequent differentiation into hematopoietic stem cells/progenitor cells and the introduction of new generation sequencing holds the potential for the resolution of ambiguities involved in HSC bone marrow transplantation. There is a change in the paradigm for HSC transplantation donor selection. Donor choice favors haploidentical HCT than cord blood. This review provides a general overview of the current events around hemopoietic stem cells, with emphasis on the rising trend of HSC transplantation, especially haploidentical stem cell transplantation.
